Bluebird Bio, facing bankruptcy, has agreed to sell itself to investment firms Carlyle and SK Capital for less than $30 million. The deal will allow the company to avoid financial ruin. Shareholders can expect to receive $3 per share initially, with an additional potential gain of $6.87 per share if the company’s gene therapies become commercially successful, reaching at least $600 million in annual revenue by 2027. This sale comes after the company’s market value dropped to just $68.4 million, putting it on the brink of collapse.
Source: https://www.statnews.com/2025/02/21/bluebird-bio-sells-itself-to-carlyle-sk-capital-for-less-than-30-million